Best Peptide for Growth Hormone Secretion Research
CJC-1295 leads growth hormone secretion research through its DAC-modified GHRH(1-29) sequence, DPP-IV resistance, and extended half-life via albumin binding. The synthetic analog dominates pulsatile GH release, somatotroph signaling, and IGF-1 upregulation studies.
TOP RECOMMENDATION
CJC-1295 — GHRH(1-29) with Drug Affinity Complex
CJC-1295 is the leading peptide for growth hormone secretion research. As a DAC-modified GHRH(1-29) analog with D-Ala² DPP-IV resistance, it delivers sustained GH release kinetics through reversible albumin binding, with a half-life of 6–8 days versus minutes for native GHRH. Published studies demonstrate CJC-1295 stimulates cAMP-mediated GH secretion from anterior pituitary somatotrophs, upregulates IGF-1 in hepatocyte cultures, and maintains elevated GH pulsatility over multi-day observation windows. Tesamorelin, a full-length GHRH(1-44) analog with trans-3-hexenoic acid conjugation, offers the complete native receptor-binding domain for physiologically comparative studies but is more expensive, more complex to synthesize, and provides shorter-duration signaling. For GH secretion kinetics, IGF-1 upregulation, and metabolic pathway research, CJC-1295’s extended half-life, lower cost, and higher purity make it the definitive choice.
WHY IT WINS
- DAC (Drug Affinity Complex) modification extends plasma half-life to 6–8 days through reversible albumin binding, enabling sustained GH release kinetics over extended study windows
- D-Ala substitution at position 2 confers resistance to dipeptidyl peptidase IV (DPP-IV) cleavage, dramatically improving metabolic stability versus native GHRH(1-29)
- Smaller 29-amino-acid structure is easier to synthesize at high purity (≥ 99.6%) and lower cost per milligram than full-length GHRH analogs
- Directly stimulates cAMP-mediated GH secretion from anterior pituitary somatotrophs via GHRH receptor with well-characterized dose-response curves
- Extensively validated in somatotroph cell lines, primary pituitary cultures, and hepatocyte IGF-1 upregulation models
APPLICATION SUITABILITY MATRIX
| RESEARCH APPLICATION | CJC-1295 | Tesamorelin |
|---|---|---|
| GH Secretion from Somatotrophs | ||
| IGF-1 Upregulation | ||
| Pulsatile Release Kinetics | ||
| DPP-IV Resistance | ||
| Albumin Binding (Extended t½) | ||
| Metabolic Stability | ||
| Cost per Experiment | ||
| Physiological Relevance (Full GHRH) |
IDEAL RESEARCH APPLICATIONS
- GH3 or primary anterior pituitary somatotroph GH secretion assays
- Hepatocyte IGF-1 expression and secretion studies
- Pulsatile vs continuous GH release kinetics research
- DPP-IV resistance and metabolic stability assays
- Adipocyte lipolysis and metabolic pathway studies
ALTERNATIVE: Tesamorelin
RUNNER-UP
Tesamorelin — GHRH(1-44) Analog — Trans-3-Hexenoic Acid Conjugate
Consider when:
- Full-length GHRH(1-44) analog retains the complete native receptor-binding domain, potentially offering more physiologically relevant signaling in comparative endocrinology studies
- Trans-3-hexenoic acid conjugation provides a different stability mechanism than DAC albumin binding, useful for comparative pharmacokinetic research
- Consider when studying the full GHRH receptor conformational response or when CJC-1295’s truncated sequence is a methodological limitation
ANALYTICAL SPECIFICATIONS
Compound
GHRH(1-29) with Drug Affinity Complex
CAS Number
863288-34-0
Purity (HPLC)
≥ 99.6%
Molecular Weight
3,367.97 g/mol
Sequence
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser
Verification
HPLC + MS per batch
FREQUENTLY ASKED QUESTIONS
Why is CJC-1295 better than Tesamorelin for GH secretion research?
CJC-1295 is a DAC-modified GHRH(1-29) analog with DPP-IV resistance and albumin-binding extended half-life (6–8 days). It delivers sustained GH release at lower cost and higher synthesis purity than Tesamorelin. Tesamorelin is a full-length GHRH(1-44) analog with different stability kinetics — superior for physiological comparative studies, but less practical for sustained-release kinetics research.
What concentration of CJC-1295 should I use in somatotroph cultures?
For GH3 rat pituitary somatotrophs or primary anterior pituitary cell cultures, CJC-1295 is typically evaluated at 0.1–10 mcg/ml in serum-free DMEM/F12. GH secretion is measured by radioimmunoassay or ELISA at 1, 3, 6, and 24 hours. Include a GHRH antagonist control (e.g., astemizole) and vehicle control for mechanistic validation.
Does CJC-1295 increase IGF-1 in hepatocyte models?
Yes. CJC-1295 stimulates GH secretion from somatotrophs, which in turn upregulates IGF-1 expression in hepatocytes (HepG2, primary human hepatocytes) via the JAK2/STAT5 pathway. Typical IGF-1 readouts (ELISA, qPCR) show significant upregulation at 24–72 hours in co-culture or conditioned media transfer models.
How does the DAC modification extend half-life?
The Drug Affinity Complex (DAC) is a reactive group conjugated to the C-terminus of GHRH(1-29) that forms a reversible covalent bond with serum albumin. This albumin binding protects the peptide from renal clearance and proteolytic degradation, extending the half-life from minutes (native GHRH) to 6–8 days.
Can CJC-1295 and Tesamorelin be compared in the same study?
Yes. Many researchers use both as comparative GHRH analog controls. CJC-1295 represents the truncated, stabilized analog approach; Tesamorelin represents the full-length, conjugated analog approach. Reconstitute each separately and normalize by molar concentration (not mass) due to their different molecular weights.
REFERENCES
- [1]Teichman, S.L. et al. (2006). Prolonged stimulation of growth hormone release by CJC-1295. Endocrine, 30(2), 201–208.
- [2]Ionescu, M. & Frohman, L.A. (2006). Pulsatile secretion of growth hormone. Growth Hormone & IGF Research, 16(1), 1–12.
- [3]Sackmann-Sala, L. et al. (2009). CJC-1295 increases GH and IGF-I levels. Growth Hormone & IGF Research, 19(4), 380–383.
- [4]Bowers, C.Y. (2010). Unnatural growth hormone-releasing peptide begets natural ghrelin. Journal of Clinical Endocrinology & Metabolism, 95(3), 1146–1148.
TOP RECOMMENDATION
CJC-1295
GHRH(1-29) with Drug Affinity Complex
QUICK LINKS
RELATED RESEARCH GOALS
RESEARCH USE ONLY. All compounds are strictly for in-vitro laboratory research by qualified professionals. Not for human consumption, veterinary use, or clinical application.